Hans Minderman

5.1k total citations
90 papers, 3.2k citations indexed

About

Hans Minderman is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Hans Minderman has authored 90 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 42 papers in Molecular Biology and 24 papers in Immunology. Recurrent topics in Hans Minderman's work include Drug Transport and Resistance Mechanisms (21 papers), Cancer therapeutics and mechanisms (17 papers) and Acute Myeloid Leukemia Research (12 papers). Hans Minderman is often cited by papers focused on Drug Transport and Resistance Mechanisms (21 papers), Cancer therapeutics and mechanisms (17 papers) and Acute Myeloid Leukemia Research (12 papers). Hans Minderman collaborates with scholars based in United States, Netherlands and Germany. Hans Minderman's co-authors include Kieran L. O’Loughlin, Maria R. Baer, Orla Maguire, William R. Greco, Xiangyang Wang, Jonah Riddell, Sandra O. Gollnick, Lakshmi Pendyala, Paul K. Wallace and Youcef M. Rustum and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Hans Minderman

89 papers receiving 3.1k citations

Peers

Countries citing papers authored by Hans Minderman

Since Specialization

Citations

This map shows the geographic impact of Hans Minderman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Minderman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Minderman more than expected).

Fields of papers citing papers by Hans Minderman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Minderman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Minderman. The network helps show where Hans Minderman may publish in the future.

Co-authorship network of co-authors of Hans Minderman

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Minderman. A scholar is included among the top collaborators of Hans Minderman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Minderman. Hans Minderman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs 2024 ·Cancer Immunology Research ·Bowen Dong, Nataša Obermajer, Takemasa Tsuji, Junko Matsuzaki, (unknown), Cindy Sander, Henry Withers, Mark D. Long, (unknown), Scott H. Olejniczak, Hans Minderman, John M. Kirkwood, Robert P. Edwards, Walter J. Storkus, Pedro Romero, Paweł Kaliński	3
2	Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx 2023 ·Journal for ImmunoTherapy of Cancer ·Shipra Gandhi, Mateusz Opyrchal, Melissa Grimm, (unknown), Kathleen M. Kokolus, Agnieszka K. Witkiewicz, Kristopher Attwood, Adrienne Groman, Lauren Williams, (unknown), Paul K. Wallace, (unknown), Hans Minderman, Orla Maguire, Tracey L. O’Connor, Amy Early, Ellis Levine, Paweł Kaliński	10
3	In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models 2021 ·Journal for ImmunoTherapy of Cancer ·Takaaki Oba, Kenichi Makino, Ryutaro Kajihara, (unknown), Ryoko Araki, Masumi Abe, Hans Minderman, Alfred E. Chang, Kunle Odunsi, Fumito Ito	30
4	Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation 2021 ·Molecular Therapy — Oncolytics ·(unknown), (unknown), M. Winkler, Prashant Kumar Singh, Eduardo Cortes, Anthony Miliotto, Song Liu, Mark D. Long, Yan Li, Aimee Stablewski, Kieran L. O’Loughlin, Hans Minderman, Kunle Odunsi, Hanna Rokita, AJ Robert McGray, Emese Zsíros, Danuta Kozbor	11
5	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s 2020 ·Nature Communications ·Takaaki Oba, Mark D. Long, Tibor Keler, Henry C. Marsh, Hans Minderman, Scott I. Abrams, Song Liu, Fumito Ito	105
6	1031P Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type I IFN signaling in solid tumours 2020 ·Annals of Oncology ·Hani M. Babiker, Erkut Borazanci, Vivek Subbiah, Alain P. Algazi, Jacob Schachter, Michal Lotem, Daniel Hendler, (unknown), Hans Minderman, Cara Haymaker, Chantale Bernatchez, Ravi Murthy, (unknown), Nadia Caplan, Gregory Woodhead, (unknown), Srinivas K. Chunduru, Peter M. Anderson, Adi Diab, Igor Puzanov	2
7	Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses 2018 ·Cancer Immunology Research ·Gautam N. Shenoy, Jenni Loyall, Orla Maguire, Vandana Iyer, Raymond J. Kelleher, Hans Minderman, Paul K. Wallace, Kunle Odunsi, Sathy V. Balu‐Iyer, Richard B. Bankert	60
8	Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1 2016 ·Molecular Cancer Therapeutics ·Lawrence J. Thomas, Laura Vitale, Thomas J. O’Neill, (unknown), Paul K. Wallace, Hans Minderman, (unknown), (unknown), (unknown), James R. Storey, (unknown), Russell A. Hammond, Jenifer Widger, Karuna Sundarapandiyan, Andrea Crocker, Henry C. Marsh, Tibor Keler	34
9	Total cellular protein presence of the transcription factor IRF8 does not necessarily correlate with its nuclear presence 2016 ·Methods ·Hans Minderman, Orla Maguire, Kieran L. O’Loughlin, Jason B. Muhitch, Paul K. Wallace, Scott I. Abrams	6
10	Identification and Characterization of Intestinal Antigen-Presenting Cells Involved in Uptake and Processing of a Nontoxic Recombinant Chimeric Mucosal Immunogen Based on Cholera Toxin Using Imaging Flow Cytometry 2013 ·Clinical and Vaccine Immunology ·Weiwei Zhao, Hans Minderman, Michael W. Russell	9
11	Image cytometry‐based detection of aneuploidy by fluorescence in situ hybridization in suspension 2012 ·Cytometry Part A ·Hans Minderman, (unknown), (unknown), Andrzej Wierzbicki, Orla Maguire, Eunice S. Wang, AnneMarie W. Block, Sheila N.J. Sait, Thaddeus C. George, Paul K. Wallace	28
12	The Prolyl Isomerase Pin1 Targets Stem-Loop Binding Protein (SLBP) To Dissociate the SLBP-Histone mRNA Complex Linking Histone mRNA Decay with SLBP Ubiquitination 2012 ·Molecular and Cellular Biology ·Nithya Krishnan, TuKiet T. Lam, Andrew J. Fritz, (unknown), Kieran L. O’Loughlin, Hans Minderman, Ronald Berezney, William F. Marzluff, Roopa Thapar	39
13	Peroxiredoxin 1 Stimulates Secretion of Proinflammatory Cytokines by Binding to TLR4 2009 ·The Journal of Immunology ·Jonah Riddell, Xiangyang Wang, Hans Minderman, Sandra O. Gollnick	180
14	Rapamycin overcomes multidrug resistance (MDR) mediated by P-glycoprotein (Pgp), Multidrug Resistance Protein-1 (MRP-1), Breast Cancer Resistance Protein (BCRP) and Lung Resistance Protein (LRP) and synergizes with substrate drugs in MDR cells. 2006 ·Cancer Research ·Attaphol Pawarode, Hans Minderman, Kieran L. O’Loughlin, William R. Greco, Maria R. Baer	3
15	Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status 2006 ·Cancer Chemotherapy and Pharmacology ·Hans Minderman, Yunfei Zhou, Kieran L. O’Loughlin, Maria R. Baer	62
16	The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells 2006 ·Investigational New Drugs ·Tracy A. Brooks, Kieran L. O’Loughlin, Hans Minderman, Brian N. Bundy, Laurie Ford, (unknown), Ralph J. Bernacki, Waldemar Priebe, Maria R. Baer	12
17	Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease‐free survival 2004 ·British Journal of Haematology ·Attaya Suvannasankha, Hans Minderman, Kieran L. O’Loughlin, Takeo Nakanishi, Laurie Ford, William R. Greco, Meir Wetzler, Douglas D. Ross, Maria R. Baer	48
18	Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023 2004 ·Cancer Chemotherapy and Pharmacology ·Hans Minderman, Tracy A. Brooks, Kieran L. O’Loughlin, Iwao Ojima, Ralph J. Bernacki, Maria R. Baer	45
19	Flow cytometric analysis of breast cancer resistance protein expression and function 2002 ·Cytometry ·Hans Minderman, Attaya Suvannasankha, Kieran L. O’Loughlin, George L. Scheffer, Rik J. Scheper, Robert W. Robey, Maria R. Baer	73
20	Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. 1993 ·PubMed ·Petra Muus, Peter Donnelly, A Schattenberg, P. Linssen, Hans Minderman, Edward Dompeling, (unknown)	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact